These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36657398)

  • 1. BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Dyring-Andersen B; Rahbek Gjerdrum LM
    Dermatology; 2023; 239(3):409-421. PubMed ID: 36657398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
    Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
    JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J
    Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
    Chen B; Tardell C; Higgins B; Packman K; Boylan JF; Niu H
    PLoS One; 2012; 7(8):e42598. PubMed ID: 22880048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.
    Verlinden I; van den Hurk K; Clarijs R; Willig AP; Stallinga CMHA; Roemen GMJM; van den Oord JJ; Zur Hausen A; Speel EM; Winnepenninckx VJL
    Medicine (Baltimore); 2014 Dec; 93(28):e285. PubMed ID: 25526463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
    Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
    Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
    Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.
    Riveiro-Falkenbach E; Santos-Briz A; Ríos-Martín JJ; Rodríguez-Peralto JL
    Am J Dermatopathol; 2017 Apr; 39(4):291-295. PubMed ID: 28323782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
    Liu W; Kelly JW; Trivett M; Murray WK; Dowling JP; Wolfe R; Mason G; Magee J; Angel C; Dobrovic A; McArthur GA
    J Invest Dermatol; 2007 Apr; 127(4):900-5. PubMed ID: 17159915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.